Core Viewpoint - Hims & Hers is attempting to sell a $49 compounded version of Novo Nordisk's Wegovy pill, which is causing turbulence in the obesity drug market and raising questions about the legality of this strategy, potentially impacting the returns of established drugmakers in the sector [1] Group 1 - Hims & Hers' new product is significantly cheaper than the original Wegovy, which may attract consumers looking for more affordable obesity treatment options [1] - The move has sparked a debate regarding the legality of selling compounded medications, which could lead to regulatory scrutiny and affect market dynamics [1] - The introduction of this compounded version threatens the profitability of major pharmaceutical companies that produce obesity drugs, as it may lead to a decrease in their market share [1]